Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,503 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The risk of serious infection in patients with rheumatoid arthritis treated with tumor necrosis factor inhibitors decreased over time: a report from the registry of Japanese rheumatoid arthritis patients on biologics for long-term safety (REAL) database.
Sakai R, Cho SK, Nanki T, Koike R, Watanabe K, Yamazaki H, Nagasawa H, Amano K, Tanaka Y, Sumida T, Ihata A, Yasuda S, Nakajima A, Sugihara T, Tamura N, Fujii T, Dobashi H, Miura Y, Miyasaka N, Harigai M; REAL study group. Sakai R, et al. Among authors: nagasawa h. Rheumatol Int. 2014 Dec;34(12):1729-36. doi: 10.1007/s00296-014-3045-8. Epub 2014 May 23. Rheumatol Int. 2014. PMID: 24852650
Pneumocystis jirovecii pneumonia associated with etanercept treatment in patients with rheumatoid arthritis: a retrospective review of 15 cases and analysis of risk factors.
Tanaka M, Sakai R, Koike R, Komano Y, Nanki T, Sakai F, Sugiyama H, Matsushima H, Kojima T, Ohta S, Ishibe Y, Sawabe T, Ota Y, Ohishi K, Miyazato H, Nonomura Y, Saito K, Tanaka Y, Nagasawa H, Takeuchi T, Nakajima A, Ohtsubo H, Onishi M, Goto Y, Dobashi H, Miyasaka N, Harigai M. Tanaka M, et al. Among authors: nagasawa h. Mod Rheumatol. 2012 Nov;22(6):849-58. doi: 10.1007/s10165-012-0615-z. Epub 2012 Feb 22. Mod Rheumatol. 2012. PMID: 22354637
Time-dependent increased risk for serious infection from continuous use of tumor necrosis factor antagonists over three years in patients with rheumatoid arthritis.
Sakai R, Komano Y, Tanaka M, Nanki T, Koike R, Nagasawa H, Amano K, Nakajima A, Atsumi T, Koike T, Ihata A, Ishigatsubo Y, Saito K, Tanaka Y, Ito S, Sumida T, Tohma S, Tamura N, Fujii T, Sugihara T, Kawakami A, Hagino N, Ueki Y, Hashiramoto A, Nagasaka K, Miyasaka N, Harigai M; Real Study Group. Sakai R, et al. Among authors: nagasawa h. Arthritis Care Res (Hoboken). 2012 Aug;64(8):1125-34. doi: 10.1002/acr.21666. Arthritis Care Res (Hoboken). 2012. PMID: 22422487 Free article.
Addition of another disease-modifying anti-rheumatic drug to methotrexate reduces the flare rate within 2 years after infliximab discontinuation in patients with rheumatoid arthritis: an open, randomized, controlled trial.
Kurasawa T, Nagasawa H, Kishimoto M, Amano K, Takeuchi T, Kameda H. Kurasawa T, et al. Among authors: nagasawa h. Mod Rheumatol. 2014 Jul;24(4):561-6. doi: 10.3109/14397595.2013.844886. Epub 2013 Nov 5. Mod Rheumatol. 2014. PMID: 24252035 Clinical Trial.
Head-to-head comparison of the safety of tocilizumab and tumor necrosis factor inhibitors in rheumatoid arthritis patients (RA) in clinical practice: results from the registry of Japanese RA patients on biologics for long-term safety (REAL) registry.
Sakai R, Cho SK, Nanki T, Watanabe K, Yamazaki H, Tanaka M, Koike R, Tanaka Y, Saito K, Hirata S, Amano K, Nagasawa H, Sumida T, Hayashi T, Sugihara T, Dobashi H, Yasuda S, Sawada T, Ezawa K, Ueda A, Fujii T, Migita K, Miyasaka N, Harigai M; REAL Study Group. Sakai R, et al. Among authors: nagasawa h. Arthritis Res Ther. 2015 Mar 23;17(1):74. doi: 10.1186/s13075-015-0583-8. Arthritis Res Ther. 2015. PMID: 25880658 Free PMC article. Clinical Trial.
1,503 results